Tables

1.1 Estimated 2004 US sales losses due to copyright piracy in 52 selected countries 10
6.1 A timeline for India’s patent law 99
6.2 Number of companies in the Indian pharmaceutical industry 100
6.3 Characteristics of the Indian pharmaceutical industry 103
6.4 India’s ten largest pharmaceutical companies by market capitalization in 2004 103
6.5 India’s ten largest pharmaceutical companies by sales in 2004 104
6.6 Strengths and opportunities for the Indian pharmaceutical industry 104
6.7 India’s top-ten pharmaceutical companies’ R&D expenditures 105
6.8 India’s domestic patent growth 108
6.9 Indian post-reform pharmaceutical patents 108
6.10 Pre- and post-reform patents for Indian pharmaceutical companies 109
6.11 Percentage of process-oriented patents in India’s pharmaceutical companies 110
13.1 Evolution of average IPR index scores for developing countries, 1990–2000 243
13.3 The relationship between merchandise import flows and patent protection, 1990–2005 249
13.5 Estimates of relationship between outward US FDI stock in developing countries and patent protection, by industry, 1990–2005 250
13.6 Royalty and licensing fees for the use of intangible assets, received from abroad by US parent firms 253
13.7 Intellectual property rights: royalty and licensing fees from unaffiliated sources, firm level 254
13.8 Intellectual property rights and US royalty and licensing fees relative to trade and foreign direct investment 255
13.9 The relationship between patent reform and high-tech licensing transactions in developing countries 257